Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target on Regeneron Pharma (NASDAQ: REGN) to $490.00 (from $461.00) following Q1 results while retaining a Neutral rating.
Pantginis commented, "Regeneron announced 1Q15 results posting GAAP EPS of $0.66 (non-GAAP of $2.88) compared with our estimate of $0.97. 1Q15 revenue came in at $869.6 million beating our estimate of $826.2 million and the consensus estimate of $824.6 million. We believe Eylea revenue and our projected Praluent approval are currently priced into the stock, but look to the clinical pipeline to identify next value drivers for the stock."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $470.01 yesterday.